Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | GRM5 | P41594 | 6/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.44 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.44 |
| ▸ | KMO | O15229 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | ERBB3 | P21860 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28111776 | 0.78 | MAPT (0.64) | MAPTMEN1KMT2AKDM4ELMNA | |
| SCHEMBL990293 | 0.77 | GRM5 (0.71) | MAPTGRM5RAB9ANPC1 | |
| SCHEMBL991601 | 0.73 | GRM5 (0.76) | MAPTGRM5KMT2ASMN1; SMN2 | |
| SCHEMBL990806 | 0.73 | GRM5 (1.00) | GRM5HPGDSMN1; SMN2 | |
| SCHEMBL11563504 | 0.72 | HCAR3 (0.73) | GRM5P4HTM | |
| SCHEMBL4042156 | 0.71 | HCAR3 (0.48) | KDM4ELMNAMAPK1P4HTMALDH1A1 | |
| SCHEMBL27730835 | 0.71 | ALDH1A1 (0.47) | MAPTKDM4ELMNAMAPK1P4HTM | |
| SCHEMBL698657 | 0.71 | KDM4E (0.52) | MAPTMEN1KMT2AKDM4ELMNA | |
| SCHEMBL4039216 | 0.70 | ALDH1A1 (0.43) | MAPTGRM5KDM4ELMNAHPGD | |
| SCHEMBL11177087 | 0.69 | TSHR (0.74) | MAPTMEN1KMT2AMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140187600-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GLATTHAR RALF (DE) | 2014-07-03 | — | — | US | disclosed |
| US-20120309742-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GLATTHAR RALF (DE) | 2012-12-06 | — | — | US | disclosed |
| EP-2272509-A1 | New Uses of metabotropic glutamate receptors | Novartis AG (CH) | 2011-01-12 | — | — | EP | disclosed |
| CN-101679299-A | Nicotinic acid derivatives as modulators of metabotropic glutamate receptor-5 | NOVARTIS AG | 2010-03-24 | — | — | CN | disclosed |
| US-20100041641-A1 | USES OF METABOTROPIC GLUTAMATE RECEPTORS | RALF GLATTHAR | 2010-02-18 | — | — | US | disclosed |
| EP-2146969-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Novartis Ag (CH) | 2010-01-27 | — | — | EP | disclosed |
| CN-101535265-A | Nicotinic acid derivatives as metabotropic glutamate receptor modulators | NOVARTIS AG (CH) | 2009-09-16 | — | — | CN | disclosed |
| US-20090105266-A1 | Organic compounds | NOVARTIS AG (CH) | 2009-04-23 | — | — | US | disclosed |
| US-20090105266-A1 | Organic compounds | NOVARTIS AG (CH) | 2009-04-23 | — | — | US | disclosed |
| US-20090105266-A1 | Organic compounds | NOVARTIS AG (CH) | 2009-04-23 | — | — | US | disclosed |
| US-20090005363-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-01-01 | — | — | US | disclosed |
| CN-101321731-A | Nicotinic acid derivatives as metabotropic glutamate receptor modulators | NOVARTIS AG (CH) | 2008-12-10 | — | — | CN | disclosed |
| WO-2008128968-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | NOVARTIS AG (CH) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008128968-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | NOVARTIS AG (CH) | 2008-10-30 | — | — | WO | disclosed |
| EP-1966144-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Novartis AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007071358-A1 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105266-A1 | Organic compounds | SLCO2B1, SLCO1B1, SLCO1B3 | MAPT 995/4885GRM5 4545/4885MEN1 2460/4885 |
| US-20100041641-A1 | USES OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM2, GRM1 | MAPT 602/4885GRM5 1/4885MEN1 4664/4885 |
| US-20120309742-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | MAPT 548/4885GRM5 1/4885MEN1 4674/4885 |
| US-20090005363-A1 | Organic Compounds | NNT, NAPRT, CHRNA5 | MAPT 884/4885GRM5 680/4885MEN1 2366/4885 |
| US-20140187600-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | MAPT 548/4885GRM5 1/4885MEN1 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.